Bronchodilator Drugs - Lithuania | Statista Market Forecast

The Bronchodilator Drugs market in Lithuania is expected to experience significant growth in the coming years.
According to projections, the revenue in this market is estimated to reach US$10.38m in 2024.
Furthermore, it is anticipated that there will be a steady annual growth rate (CAGR 2024-2029) of 3.87%, leading to a market volume of US$12.55m by 2029.
When comparing in Lithuania to other countries globally, it is worth noting that United States will generate the highest revenue in the Bronchodilator Drugs market, with an estimated amount of US$17.34bn in 2024.
Lithuania's market for bronchodilator drugs is witnessing a surge in demand due to the high prevalence of respiratory conditions in the country.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are an essential part of the pharmaceutical industry, catering to the needs of patients suffering from respiratory disorders. The Bronchodilator Drugs market in Lithuania has been growing steadily over the years due to various factors.

Customer preferences: Patients suffering from respiratory disorders prefer bronchodilator drugs due to their quick action and effectiveness in treating symptoms like coughing, wheezing, and shortness of breath. The demand for these drugs has been increasing in Lithuania due to the rising prevalence of respiratory disorders like asthma and chronic obstructive pulmonary disease (COPD).

Trends in the market: One of the major trends in the Bronchodilator Drugs market in Lithuania is the increasing focus on research and development activities to improve the efficacy of these drugs. Pharmaceutical companies are investing heavily in developing new bronchodilator drugs that are more effective and have fewer side effects. Another trend is the growing popularity of combination therapy, where two or more drugs are combined to provide better relief to patients suffering from respiratory disorders.

Local special circumstances: Lithuania has a high prevalence of respiratory disorders like asthma and COPD, which has been driving the demand for bronchodilator drugs in the country. Additionally, the aging population in Lithuania has been contributing to the growth of the market as older adults are more prone to respiratory disorders. The government in Lithuania has also been taking initiatives to improve the healthcare infrastructure in the country, which has been boosting the demand for bronchodilator drugs.

Underlying macroeconomic factors: The Bronchodilator Drugs market in Lithuania is also influenced by various macroeconomic factors. The growing healthcare industry in the country, coupled with the increasing disposable income of the population, has been driving the demand for these drugs. Additionally, the presence of major pharmaceutical companies in Lithuania has been contributing to the growth of the market. The easy availability of these drugs through various channels like pharmacies, hospitals, and online platforms has also been a major factor driving the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.